MLNT - Melinta Therapeutics Inc.
Previous close
0.5
0 0%
Share volume: 0
Last Updated: Fri 10 Jan 2020 06:00:00 AM CET
Pharmaceuticals: Other:
0%
PREVIOUS CLOSE
CHG
CHG%
$0.50
0.00
0.00%
Fundamental analysis
36%
Profitability
50%
Dept financing
17%
Liquidity
19%
Performance
32%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
0 0%
6 Months
0 0%
1 Year
0 0%
2 Year
0 0%
Key data
Stock price
$0.50
DAY RANGE
$0.50 - $0.50
52 WEEK RANGE
$0.31 - $0.46
52 WEEK CHANGE
$0.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Jennifer A. Sanfilippo
Region: US
Website: http://www.melinta.com
Employees: 290
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology
Region: US
Website: http://www.melinta.com
Employees: 290
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology
Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in Morristown, NJ.
Recent news